Atrovastatin for Preventing Atrial Fibrillation Following Open Cardiac Valve Repair

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the investigation is to determine whether Atrovastatin as anti-inflammatory agent can be effective in preventing from atrial fibrillation incidence in patients whom undergone open cardiac surgery for their heart valve repair.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Urmia University of Medical Sciences
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• Greater than 25 y/o

• No occurrence of intra- or post-operative cardiopulmonary arrest

• Not consuming drugs affecting atrial rhythm

• Having sinus rhythm before surgery

• Lack of paroxysmal atrial fibrillation history

• Only undergo heart valve surgery

• Lack of considerable heart ischemia needed atorvastatin use

• Routine cares in ward, post-operative ward, and intensive care unit were done

Exclusion Criteria:

• Lesser than 25 y/o

• History of atrial fibrillation

• History of taking anti-arrhythmic drugs

• History of implementing pacemakers

• Severe heart failure

• Renal failure

• Hepatic failure

• Severe pulmonary diseases

• Heart block or bradyarrhythmia

• Routine cares in ward, post-operative ward, and intensive care unit were not done

• Performing concomitant cardiac surgery except valve repair

• Having considerable heart ischemia needed atorvastatin use